+
Site Tour

Dr Ingo Eitel explains why LAAO can be an option in ESKD patients 

Dr Ingo Eitel explains why left atrial appendage occlusion can be an option in end stage kidney disease (ESKD) patients 

LEARN MORE:

Amplatzer LAA Occluder

Related Videos

Structural Interventions: Left Atrial Appendage Occlusion (LAAO)

Anatomy for structural interventions therapies (ASD, PFO, LAAO)

EHRA 2026 | Tutorials | PFA/LAAO

LAAO Summit Introduction

LAAO Summit Closing Session

Case Review D. Nair

Strategic Planning for Concomitant Procedures A. Lepillier

PFA Meets LAAO L. Boldt

TRENDING TOPICS

Procedural tip & tricks with Navitor across all valve sizes

Mastering TAVI implantation: procedural tricks with Navitor across all valve sizes

1-year VANTAGE TAVI outcomes in low/intermediate-risk patients

What are the learnings from the one-year VANTAGE TAVI outcomes in low/intermediate-risk patients?

Transcatheter Aortic Valves Implant

Advancing TAVI Practice with Navitor™

CONNEXT


HUB
RELATED RESOURCES

The Amulet IDE Trial

Amplatzer™ Amulet™ LAA Occluder

Data Summary PFO closure in patients > 60 Years

ESOC presentation: PFO closure in patients > 60 Years

CONNEXT


LIVE
RELATED EVENTS

Structural Interventions: Left Atrial Appendage Occlusion (LAAO)

Anatomy for structural interventions therapies (ASD, PFO, LAAO)

LAAO Summit Introduction

LAAO Summit Closing Session

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline